From Pills to Pivots: How a $30M Pharma Nanocap Gobbled 9% of $SKY

NovaBay Pharmaceuticals, a nanocap biotech firm valued at a mere $30 million, has officially swapped its petri dishes for private keys. The company has rebranded as the Stablecoin Development Corporation and changed its stock ticker from NBY to SDEV, executing a full-scale pivot from healthcare to crypto—a move that makes most degen plays look conservative.

This corporate metamorphosis was bankrolled by a hefty $134 million private placement, with backing from heavyweights Framework Ventures and Tether Investments. The newly filled war chest is being aggressively deployed to build a whale-sized position in SKY, the governance token for the Sky protocol, which is the DeFi engine behind the dollar-pegged stablecoin USDS.

The firm now sits on a mountain of roughly 2.06 billion SKY tokens, representing about 8.78% of the entire supply. At today's prices, that digital hoard is valued at approximately $147 million—talk about a glow-up. More than half of these tokens were scooped up on the open market at an average price around $0.065, with the rest bundled into the financing deal that also included cash and stablecoins.

Not satisfied with merely diamond-handing its bag, the company has thrown its SKY into the staking pools to farm rewards. To date, it reports harvesting an additional 26.6 million SKY tokens, with yields fluctuating based on the protocol's ever-changing participation rules—because in DeFi, the only constant is variable APY.

The Sky protocol, a spiritual successor to MakerDAO, currently offers a staking rate north of 10%. In a twist of market irony, while the broader crypto market has climbed 4%, SKY's price has dipped about 1.45% over the past day. Meanwhile, the company's old stock ticker, NBY, enjoyed a 5% bump on the news—proving that sometimes the legacy equity bagholders win, too.

CoinDesk mentioned it reached out to the newly minted Stablecoin Development Corp for comment but, as of publication, was met with radio silence. The silence is deafening, but the on-chain activity speaks volumes.